CG Oncology (CGON) Cash from Operations (2023 - 2026)
CG Oncology (CGON) reported Cash from Operations of 56900000.0 for Q1 2026, down 94.35% on a YoY basis from 1007171281.74 in Q1 2025, and down 56.98% quarter-over-quarter from 36246000.0 in Q4 2025.
CG Oncology (CGON) Cash from Operations (2023 - 2026) Analysis & Trends
CG Oncology has reported Cash from Operations for 4 years, with the latest figure at 56900000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 94.35% year-over-year to 56900000.0; the trailing twelve-month figure through Mar 2026 stood at 159969000.0 (down 95.14% YoY), and the FY2025 full-year result was 132346000.0, down 68.14% from the prior year.
- Cash from Operations for Q1 2026 stood at 56900000.0, down from 36246000.0 in the prior quarter.
- The five-year high for Cash from Operations was 7986000.0 in Q1 2023, with the low at 56900000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 24126000.0 across 4 years, with a median of 20662000.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 225.72% — and 2025, when it retreated 12.55%.
- CG Oncology's Cash from Operations stood at 14645000.0 in 2023, then plunged by 41.09% to 20662000.0 in 2024, then tumbled by 75.42% to 36246000.0 in 2025, then sank by 56.98% to 56900000.0 in 2026.
- The last three Cash from Operations figures came in at 56900000.0 (Q1 2026), 36246000.0 (Q4 2025), and 38900000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn | -56.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.90 Mn |
| Mar 31, 2026 | -56.90 Mn |
| Dec 31, 2025 | -36.25 Mn |
| Dec 31, 2025 | -36.25 Mn |
| Sep 30, 2025 | -38.90 Mn |
| Sep 30, 2025 | -38.90 Mn |
| Jun 30, 2025 | -27.92 Mn |
| Jun 30, 2025 | -27.92 Mn |
| Mar 31, 2025 | -29.28 Mn |
| Mar 31, 2025 | -29.28 Mn |
| Dec 31, 2024 | -20.66 Mn |
| Dec 31, 2024 | -20.66 Mn |
| Sep 30, 2024 | -15.92 Mn |
| Sep 30, 2024 | -15.92 Mn |
| Jun 30, 2024 | -16.12 Mn |
| Jun 30, 2024 | -16.12 Mn |
| Mar 31, 2024 | -26.01 Mn |
| Mar 31, 2024 | -26.01 Mn |
| Dec 31, 2023 | -14.65 Mn |
| Dec 31, 2023 | -14.65 Mn |